Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

AZZ CEO David Dingus Diagnosed With Pancreatic Cancer

RELATED NEWS
Trade AZZ now with 

AZZ Inc. (AZZ: Quote) said Monday that its President and Chief Executive Officer, David Dingus, has been recently diagnosed with cancer of the pancreas.

Dingus will begin an aggressive treatment commencing the week of March 4.

It is anticipated that during this period of treatment, all day-to-day operations will continue to be conducted by the organization currently in place, the company said and added that Dingus will continue in his role of Chief Executive Officer.

AZZ said Dingus and the senior management team will continue to work with the Board of Directors to continue to seek out all opportunities for profit enhancement, growth and expansion of the existing businesses and the successful implementation of the Aquilex SRO acquisition should the company receive the anticipated government approval to proceed.

Dingus may have a reduced work schedule during certain periods of his treatment, but he is not expected to be away for any extended periods of time, the company noted.

Click here to receive FREE breaking news email alerts for AZZ incorporated and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%. Here is a quick summary of the earnings reported after the bell on Nov. 24. 1. Amira Nature Foods Ltd (ANFI) reported net income for the second quarter of $8.3 million or $0.29 per share, compared to $5.0 million or $0.18 per share for the year-ago quarter. Excluding items, adjusted earnings...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.